Abstract
BackgroundBladder cancer was a malignant disease in patients, our research aimed at discovering the possible biomarkers for the diseases.ResultsThe gene chip GSE31684, including 93samples, was downloaded from the GEO datasets and co-expression network was constructed by the data. Molecular complex detection(MCODE) was used to identify hub genes. The most significant cluster including 16 genes: CDH11, COL3A1, COL6A3, COL5A1, AEBP1, COL1A2, NTM, COL11A1, THBS2, COL8A1, COL1A1, BGN, MMP2, PXDN, THY1, and TGFB1I1 was identified. After annotated by BiNGO, they were suggested associated with collagen fibril organization and blood vessel development. In addition, the Kaplan Meier curves were obtained by UALCAN. The high expression of THY1, AEBP1, CDH11, COL1A1, COL1A2, COL11A1, MMP2, PXDN, BGN, COL5A1, COL8A1, and TGFB1I1 indicated poor prognosis of the patients(P < 0.05). Finally, we examined genes’ expression between low and high tumor stage by the Wilcoxon test(P < 0.05), TGFB1I1 was excluded.ConclusionTHY1, AEBP1, CDH11, COL1A1, COL1A2, COL11A1, MMP2, PXDN, BGN, COL5A1, COL8A1 associated with the tumor stage as well as tumor patients’ prognosis. COL5A1, COL8A1(P < 0.01) may serve as therapeutic targets for the disease.
Highlights
Bladder cancer was a malignant disease in patients, our research aimed at discovering the possible biomarkers for the diseases
The survival rate of bladder carcinoma sharply declined with the spreading of the tumor
There were four types of standard treatment for bladder cancer including surgery, radiation therapy, chemotherapy, and immunotherapy; surgery was the primary method in clinical trials [3]
Summary
Data collection The gene chip GSE31684 [19] of bladder cancer with its clinical manifestation data was downloaded from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). The platform was GPL570(Affymetrix Human Genome U133 Plus 2.0), and there were 93 bladder cancers samples with several clinical variables. The raw data had been processed, Items Counts value Gender Male Female Age at diagnosis 69.13± 10.15(years) Survival Months 47.47± 44.52(months)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
